NCT05483855

Brief Summary

Objective 1: Evaluate patients' satisfaction with their telehealth care and determine factors associated with satisfaction. Objective 2: Deploy PROs and patient self-assessment tools, specifically a patient-facing instructional in-app tool that instructs RA patients how to perform self-assessment examinations to observe and report the number of tender and swollen joint counts.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,580

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 27, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 2, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

January 3, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

August 6, 2024

Status Verified

August 1, 2024

Enrollment Period

1.9 years

First QC Date

July 27, 2022

Last Update Submit

August 5, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Correlation between patient joint count and provider joint count

    The investigators will examine and compare the patient and rheumatology provider's tender and swollen joint count summed scores and Pearson and Spearman's correlation coefficient (if the data is non-normally distributed). The investigators will also calculate a typical Clinical Disease Index (CDAI) for RA which is a composite score of TJC28 + SJC28 + Patient Global + Provider Global and correlate with the patient \[p\] CDAI (\[p\]TJC28 + \[p\]SJC28 + Patient Global + Provider Global). Disease remission for RA is denoted by a CDAI composite score of less than or equal to 2.8 while high RA disease activity is denoted by a CDAI score of 22 or greater. The investigators will also compute weighted kappa statistics, comparing the 4x4 table of remission, low moderate, and high disease activity categories, using the traditional CDAI cut points (2.8, 10, and 22).

    Immediately after the intervention

Study Arms (2)

Objective 1: Telehealth Visit

Any rheumatology patient, seen and treated by a participating physician, who is 19 years and older, with the target condition(s) of interest, and is already scheduled for a telehealth visit.

Other: Objective 1 Only: Telehealth Satisfaction Survey

Objective 2: ArthritisPower App

Patients diagnosed with Rheumatoid Arthritis who already have a pre-scheduled in-office visit.

Other: Objective 2 Only: ArthritisPower Joint Assessment

Interventions

Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.

Objective 1: Telehealth Visit

RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.

Objective 2: ArthritisPower App

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults with Rheumatoid Arthritis seen in a Rheumatology Clinic.

You may qualify if:

  • Must be 19 years or older.
  • Must have a prior diagnosis of Rheumatoid Arthritis.
  • Must be able to read and write in English or Spanish.

You may not qualify if:

  • Younger than 19 years of age
  • Does not have a prior diagnosis of Rheumatoid Arthritis.
  • Unable to read and write in English or Spanish

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Attune Health Research Inc

Beverly Hills, California, 90211, United States

RECRUITING

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 27, 2022

First Posted

August 2, 2022

Study Start

January 3, 2023

Primary Completion

December 1, 2024

Study Completion

April 1, 2025

Last Updated

August 6, 2024

Record last verified: 2024-08

Locations